Arthur E. Frankel - Publications

Wake Forest University, Winston-Salem, NC, United States 
 2013- University of Texas Southwestern Medical Center, Dallas, TX, United States 
Oncology, Biochemistry, Molecular Biology

60 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2015 Bekdash A, Darwish M, Timsah Z, Kassab E, Ghanem H, Najjar V, Ghosn M, Nasser S, El-Hajj H, Bazerbachi A, Liu S, Leppla SH, Frankel AE, Abi-Habib RJ. Phospho-MEK1/2 and uPAR Expression Determine Sensitivity of AML Blasts to a Urokinase-Activated Anthrax Lethal Toxin (PrAgU2/LF). Translational Oncology. 8: 347-57. PMID 26500025 DOI: 10.1016/j.tranon.2015.07.001  0.56
2015 Burrage LC, Sun Q, Elsea SH, Jiang MM, Nagamani SC, Frankel AE, Stone E, Alters SE, Johnson DE, Rowlinson SW, Georgiou G, Lee BH. Human recombinant arginase enzyme reduces plasma arginine in mouse models of arginase deficiency. Human Molecular Genetics. PMID 26358771 DOI: 10.1093/hmg/ddv352  0.56
2015 Frankel AE, Woo JH, Ahn C, Foss FM, Duvic M, Neville PH, Neville DM. Resimmune, an anti-CD3ε recombinant immunotoxin, induces durable remissions in patients with cutaneous T-cell lymphoma. Haematologica. 100: 794-800. PMID 25795722 DOI: 10.3324/haematol.2015.123711  0.56
2015 Bachanova V, Frankel AE, Cao Q, Lewis D, Grzywacz B, Verneris MR, Ustun C, Lazaryan A, McClune B, Warlick ED, Kantarjian H, Weisdorf DJ, Miller JS, Vallera DA. Phase I study of a bispecific ligand-directed toxin targeting CD22 and CD19 (DT2219) for refractory B-cell malignancies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 1267-72. PMID 25770294 DOI: 10.1158/1078-0432.CCR-14-2877  0.56
2015 Khoury O, Ghazale N, Stone E, El-Sibai M, Frankel AE, Abi-Habib RJ. Human recombinant arginase I (Co)-PEG5000 [HuArgI (Co)-PEG5000]-induced arginine depletion is selectively cytotoxic to human glioblastoma cells. Journal of Neuro-Oncology. 122: 75-85. PMID 25567351 DOI: 10.1007/s11060-014-1698-5  0.56
2015 Rakheja D, Fuda F, Vandergriff T, Boriack R, Medeiros BC, Frankel AE, Chen W. Increased plasma d-2-hydroxyglutarate in isocitrate dehydrogenase 2-mutated blastic plasmacytoid dendritic cell neoplasm. Human Pathology. 46: 322-6. PMID 25481493 DOI: 10.1016/j.humpath.2014.10.013  0.56
2014 Agrawal V, Woo JH, Mauldin JP, Stone EM, Meininger CJ, Jo C, Kleypas K, Frenkel EP, Frankel AE. In-vivo evaluation of human recombinant Co-arginase against A375 melanoma xenografts. Melanoma Research. 24: 556-67. PMID 25304236 DOI: 10.1097/CMR.0000000000000119  0.56
2014 Frolova O, Benito J, Brooks C, Wang RY, Korchin B, Rowinsky EK, Cortes J, Kantarjian H, Andreeff M, Frankel AE, Konopleva M. SL-401 and SL-501, targeted therapeutics directed at the interleukin-3 receptor, inhibit the growth of leukaemic cells and stem cells in advanced phase chronic myeloid leukaemia. British Journal of Haematology. 166: 862-74. PMID 24942980 DOI: 10.1111/bjh.12978  0.56
2014 Frankel AE, Woo JH, Ahn C, Pemmaraju N, Medeiros BC, Carraway HE, Frankfurt O, Forman SJ, Yang XA, Konopleva M, Garnache-Ottou F, Angelot-Delettre F, Brooks C, Szarek M, Rowinsky E. Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood. 124: 385-92. PMID 24859366 DOI: 10.1182/blood-2014-04-566737  0.56
2013 Frankel AE. Special issue of clinical pharmacology: advances and applications in new protein therapeutics modulating tumor immunity. Clinical Pharmacology : Advances and Applications. 5: 1-3. PMID 24353448 DOI: 10.2147/CPAA.S55613  0.56
2013 Tanios R, Bekdash A, Kassab E, Stone E, Georgiou G, Frankel AE, Abi-Habib RJ. Human recombinant arginase I(Co)-PEG5000 [HuArgI(Co)-PEG5000]-induced arginine depletion is selectively cytotoxic to human acute myeloid leukemia cells. Leukemia Research. 37: 1565-71. PMID 24018014 DOI: 10.1016/j.leukres.2013.08.007  0.56
2013 Kassab E, Darwish M, Timsah Z, Liu S, Leppla SH, Frankel AE, Abi-Habib RJ. Cytotoxicity of anthrax lethal toxin to human acute myeloid leukemia cells is nonapoptotic and dependent on extracellular signal-regulated kinase 1/2 activity. Translational Oncology. 6: 25-32. PMID 23418614 DOI: 10.1593/tlo.12313  0.56
2013 Yoon JK, Frankel AE, Feun LG, Ekmekcioglu S, Kim KB. Arginine deprivation therapy for malignant melanoma. Clinical Pharmacology : Advances and Applications. 5: 11-9. PMID 23293541 DOI: 10.2147/CPAA.S37350  0.56
2013 Yang X, Kessler E, Su LJ, Thorburn A, Frankel AE, Li Y, La Rosa FG, Shen J, Li CY, Varella-Garcia M, Glodé LM, Flaig TW. Diphtheria toxin-epidermal growth factor fusion protein DAB389EGF for the treatment of bladder cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 148-57. PMID 23172881 DOI: 10.1158/1078-0432.CCR-12-1258  0.56
2013 Agrawal V, Woo JH, Borthakur G, Kantarjian H, Frankel AE. Red blood cell-encapsulated L-asparaginase: potential therapy of patients with asparagine synthetase deficient acute myeloid leukemia. Protein and Peptide Letters. 20: 392-402. PMID 23016580 DOI: 10.2174/092986613805290426  0.56
2012 Kandadi MR, Yu X, Frankel AE, Ren J. Cardiac-specific catalase overexpression rescues anthrax lethal toxin-induced cardiac contractile dysfunction: role of oxidative stress and autophagy. Bmc Medicine. 10: 134. PMID 23134810 DOI: 10.1186/1741-7015-10-134  0.56
2012 Kandadi MR, Frankel AE, Ren J. Toll-like receptor 4 knockout protects against anthrax lethal toxin-induced cardiac contractile dysfunction: role of autophagy. British Journal of Pharmacology. 167: 612-26. PMID 22612289 DOI: 10.1111/j.1476-5381.2012.02040.x  0.56
2012 Kuo SR, Tahir SA, Park S, Thompson TC, Coffield S, Frankel AE, Liu JS. Anti-caveolin-1 antibodies as anti-prostate cancer therapeutics. Hybridoma (2005). 31: 77-86. PMID 22509911 DOI: 10.1089/hyb.2011.0100  0.56
2012 Mauldin JP, Zeinali I, Kleypas K, Woo JH, Blackwood RS, Jo CH, Stone EM, Georgiou G, Frankel AE. Recombinant human arginase toxicity in mice is reduced by citrulline supplementation. Translational Oncology. 5: 26-31. PMID 22348173 DOI: 10.1593/tlo.11262  0.56
2012 Agrawal V, Alpini SE, Stone EM, Frenkel EP, Frankel AE. Targeting methionine auxotrophy in cancer: discovery & exploration. Expert Opinion On Biological Therapy. 12: 53-61. PMID 22171665 DOI: 10.1517/14712598.2012.636349  0.56
2012 Agrawal V, Woo JH, Mauldin JP, Jo C, Stone EM, Georgiou G, Frankel AE. Cytotoxicity of human recombinant arginase I (Co)-PEG5000 in the presence of supplemental L-citrulline is dependent on decreased argininosuccinate synthetase expression in human cells. Anti-Cancer Drugs. 23: 51-64. PMID 21955999 DOI: 10.1097/CAD.0b013e32834ae42b  0.56
2011 Frankel AE, Carter C, Kuo SR, Woo JH, Mauldin J, Liu JS. TEM8 targeted cancer therapy. Anti-Cancer Agents in Medicinal Chemistry. 11: 983-92. PMID 22023048  0.56
2011 Yang MY, Chaudhary A, Seaman S, Dunty J, Stevens J, Elzarrad MK, Frankel AE, St Croix B. The cell surface structure of tumor endothelial marker 8 (TEM8) is regulated by the actin cytoskeleton. Biochimica Et Biophysica Acta. 1813: 39-49. PMID 21129411 DOI: 10.1016/j.bbamcr.2010.11.013  0.56
2010 Vanderlaag K, Su Y, Frankel AE, Burghardt RC, Barhoumi R, Chadalapaka G, Jutooru I, Safe S. 1,1-Bis(3'-indolyl)-1-(p-substituted phenyl)methanes induce autophagic cell death in estrogen receptor negative breast cancer. Bmc Cancer. 10: 669. PMID 21129193 DOI: 10.1186/1471-2407-10-669  0.56
2010 Kandadi MR, Hua Y, Ma H, Li Q, Kuo SR, Frankel AE, Ren J. Anthrax lethal toxin suppresses murine cardiomyocyte contractile function and intracellular Ca2+ handling via a NADPH oxidase-dependent mechanism. Plos One. 5: e13335. PMID 20967205 DOI: 10.1371/journal.pone.0013335  0.56
2010 Woo JH, Lee YJ, Neville DM, Frankel AE. Pharmacology of anti-CD3 diphtheria immunotoxin in CD3 positive T-cell lymphoma trials Methods in Molecular Biology (Clifton, N.J.). 651: 157-175. PMID 20686966 DOI: 10.1007/978-1-60761-786-0_10  0.56
2010 Vallera DA, Oh S, Chen H, Shu Y, Frankel AE. Bioengineering a unique deimmunized bispecific targeted toxin that simultaneously recognizes human CD22 and CD19 receptors in a mouse model of B-cell metastases Molecular Cancer Therapeutics. 9: 1872-1883. PMID 20530709 DOI: 10.1158/1535-7163.MCT-10-0203  0.56
2010 Kim HP, Frankel AE, Hogge DE. A diphtheria toxin interleukin-3 fusion protein synergizes with tyrosine kinase inhibitors in killing leukemic progenitors from BCR/ABL positive acute leukemia Leukemia Research. 34: 1035-1042. PMID 20137810 DOI: 10.1016/j.leukres.2009.12.008  0.56
2010 Alfano RW, Leppla SH, Liu S, Bugge TH, Ortiz JM, Lairmore TC, Duesbery NS, Mitchell IC, Nwariaku F, Frankel AE. Inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin in an orthotopic model of anaplastic thyroid carcinoma Molecular Cancer Therapeutics. 9: 190-201. PMID 20053778 DOI: 10.1158/1535-7163.MCT-09-0694  0.56
2010 Su Y, Li SY, Ghosh S, Ortiz J, Hogge DE, Frankel AE. Characterization of variant diphtheria toxin-interleukin-3 fusion protein, DTIL3K116W, for phase I clinical trials. Biologicals : Journal of the International Association of Biological Standardization. 38: 144-9. PMID 19783458 DOI: 10.1016/j.biologicals.2009.08.016  0.56
2009 Kuo SR, Alfano RW, Frankel AE, Liu JS. Antibody internalization after cell surface antigen binding is critical for immunotoxin development. Bioconjugate Chemistry. 20: 1975-82. PMID 19785403 DOI: 10.1021/bc900333j  0.56
2009 Horita H, Thorburn J, Frankel AE, Thorburn A. EGFR-targeted diphtheria toxin stimulates TRAIL killing of glioblastoma cells by depleting anti-apoptotic proteins. Journal of Neuro-Oncology. 95: 175-84. PMID 19449148 DOI: 10.1007/s11060-009-9914-4  0.56
2009 Frankel AE, Woo JH. Bispecific immunotoxins. Leukemia Research. 33: 1173-4. PMID 19406472 DOI: 10.1016/j.leukres.2009.03.037  0.56
2009 Liu S, Bugge TH, Frankel AE, Leppla SH. Dissecting the urokinase activation pathway using urokinase-activated anthrax toxin Methods in Molecular Biology. 539: 175-190. PMID 19377974 DOI: 10.1007/978-1-60327-003-8_10  0.56
2009 Alfano RW, Leppla SH, Liu S, Bugge TH, Meininger CJ, Lairmore TC, Mulne AF, Davis SH, Duesbery NS, Frankel AE. Matrix metalloproteinase-activated anthrax lethal toxin inhibits endothelial invasion and neovasculature formation during in vitro morphogenesis Molecular Cancer Research. 7: 452-461. PMID 19372576 DOI: 10.1158/1541-7786.MCR-08-0451  0.56
2008 Horita H, Frankel AE, Thorburn A. Acute myeloid leukemia-targeted toxin activates both apoptotic and necroptotic death mechanisms. Plos One. 3: e3909. PMID 19079542 DOI: 10.1371/journal.pone.0003909  0.56
2008 Awasthi S, Singhal SS, Awasthi YC, Martin B, Woo JH, Cunningham CC, Frankel AE. RLIP76 and Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 4372-7. PMID 18628450 DOI: 10.1158/1078-0432.CCR-08-0145  0.56
2008 Ding Y, Boguslawski EA, Berghuis BD, Young JJ, Zhang Z, Hardy K, Furge K, Kort E, Frankel AE, Hay RV, Resau JH, Duesbery NS. Mitogen-activated protein kinase kinase signaling promotes growth and vascularization of fibrosarcoma. Molecular Cancer Therapeutics. 7: 648-58. PMID 18319331 DOI: 10.1158/1535-7163.MCT-07-2229  0.56
2008 Woo JH, Bour SH, Dang T, Lee YJ, Park SK, Andreas E, Kang SH, Liu JS, Neville DM, Frankel AE. Preclinical studies in rats and squirrel monkeys for safety evaluation of the bivalent anti-human T cell immunotoxin, A-dmDT390-bisFv(UCHT1). Cancer Immunology, Immunotherapy : Cii. 57: 1225-39. PMID 18256829 DOI: 10.1007/s00262-008-0457-x  0.56
2008 Woo JH, Liu JS, Kang SH, Singh R, Park SK, Su Y, Ortiz J, Neville DM, Willingham MC, Frankel AE. GMP production and characterization of the bivalent anti-human T cell immunotoxin, A-dmDT390-bisFv(UCHT1) for phase I/II clinical trials Protein Expression and Purification. 58: 1-11. PMID 18160309 DOI: 10.1016/j.pep.2007.11.006  0.56
2007 Depeille P, Young JJ, Boguslawski EA, Berghuis BD, Kort EJ, Resau JH, Frankel AE, Duesbery NS. Anthrax lethal toxin inhibits growth of and vascular endothelial growth factor release from endothelial cells expressing the human herpes virus 8 viral G protein coupled receptor. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 5926-34. PMID 17908989 DOI: 10.1158/1078-0432.CCR-07-0732  0.56
2007 Singh R, Browning JL, Abi-Habib R, Wong K, Williams SA, Merchant R, Denmeade SR, Buckley TJ, Frankel AE. Recombinant prostate-specific antigen proaerolysin shows selective protease sensitivity and cell cytotoxicity. Anti-Cancer Drugs. 18: 809-16. PMID 17581303 DOI: 10.1097/CAD.0b013e3280bad82d  0.56
2007 Watson LE, Mock J, Lal H, Lu G, Bourdeau RW, Tang WJ, Leppla SH, Dostal DE, Frankel AE. Lethal and edema toxins of anthrax induce distinct hemodynamic dysfunction. Frontiers in Bioscience : a Journal and Virtual Library. 12: 4670-5. PMID 17485403 DOI: 10.2741/2416  0.56
2007 Suh DY, Frankel AE. Advances in AML immunotherapy: the case for T-bodies. Leukemia Research. 31: 127-8. PMID 17137625 DOI: 10.1016/j.leukres.2006.05.002  0.56
2006 Abi-Habib RJ, Singh R, Leppla SH, Greene JJ, Ding Y, Berghuis B, Duesbery NS, Frankel AE. Systemic anthrax lethal toxin therapy produces regressions of subcutaneous human melanoma tumors in athymic nude mice. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 7437-43. PMID 17189417 DOI: 10.1158/1078-0432.CCR-06-2019  0.56
2006 Abi-Habib RJ, Singh R, Liu S, Bugge TH, Leppla SH, Frankel AE. A urokinase-activated recombinant anthrax toxin is selectively cytotoxic to many human tumor cell types. Molecular Cancer Therapeutics. 5: 2556-62. PMID 17041100 DOI: 10.1158/1535-7163.MCT-06-0315  0.56
2005 Abi-Habib RJ, Urieto JO, Liu S, Leppla SH, Duesbery NS, Frankel AE. BRAF status and mitogen-activated protein/extracellular signal-regulated kinase kinase 1/2 activity indicate sensitivity of melanoma cells to anthrax lethal toxin. Molecular Cancer Therapeutics. 4: 1303-10. PMID 16170021 DOI: 10.1158/1535-7163.MCT-05-0145  0.56
2005 Frankel AE, Kreitman RJ. CLL immunotoxins. Leukemia Research. 29: 985-6. PMID 16038723 DOI: 10.1016/j.leukres.2005.02.008  0.56
2005 Cohen KA, Liu TF, Cline JM, Wagner JD, Hall PD, Frankel AE. Safety evaluation of DT388IL3, a diphtheria toxin/interleukin 3 fusion protein, in the cynomolgus monkey. Cancer Immunology, Immunotherapy : Cii. 54: 799-806. PMID 15614527 DOI: 10.1007/s00262-004-0643-4  0.56
2004 Westcott MM, Abi-Habib RJ, Cohen KA, Willingham MC, Liu S, Bugge TH, Leppla SH, Frankel AE. Diphtheria toxin-murine granulocyte-macrophage colony-stimulating factor-induced hepatotoxicity is mediated by Kupffer cells. Molecular Cancer Therapeutics. 3: 1681-9. PMID 15634662  0.56
2004 Cohen KA, Liu TF, Cline JM, Wagner JD, Hall PD, Frankel AE. Toxicology and pharmacokinetics of DT388IL3, a fusion toxin consisting of a truncated diphtheria toxin (DT388) linked to human interleukin 3 (IL3), in cynomolgus monkeys. Leukemia & Lymphoma. 45: 1647-56. PMID 15370220 DOI: 10.1080/10428190410001663572  0.56
2004 Abi-Habib RJ, Liu S, Bugge TH, Leppla SH, Frankel AE. A urokinase-activated recombinant diphtheria toxin targeting the granulocyte-macrophage colony-stimulating factor receptor is selectively cytotoxic to human acute myeloid leukemia blasts. Blood. 104: 2143-8. PMID 15161668 DOI: 10.1182/blood-2004-01-0339  0.56
2004 Frankel AE, Gill PS. VEGF and myeloid leukemias. Leukemia Research. 28: 675-7. PMID 15158088 DOI: 10.1016/j.leukres.2003.12.013  0.56
2004 Urieto JO, Liu T, Black JH, Cohen KA, Hall PD, Willingham MC, Pennell LK, Hogge DE, Kreitman RJ, Frankel AE. Expression and purification of the recombinant diphtheria fusion toxin DT388IL3 for phase I clinical trials. Protein Expression and Purification. 33: 123-33. PMID 14680969 DOI: 10.1016/j.pep.2003.09.003  0.56
2003 Frankel AE, Neville DM, Bugge TA, Kreitman RJ, Leppla SH. Immunotoxin therapy of hematologic malignancies. Seminars in Oncology. 30: 545-57. PMID 12939723 DOI: 10.1016/S0093-7754(03)00241-0  0.56
2003 Liu TF, Cohen KA, Ramage JG, Willingham MC, Thorburn AM, Frankel AE. A diphtheria toxin-epidermal growth factor fusion protein is cytotoxic to human glioblastoma multiforme cells. Cancer Research. 63: 1834-7. PMID 12702570  0.56
2003 Ramage JG, Vallera DA, Black JH, Aplan PD, Kees UR, Frankel AE. The diphtheria toxin/urokinase fusion protein (DTAT) is selectively toxic to CD87 expressing leukemic cells. Leukemia Research. 27: 79-84. PMID 12479856 DOI: 10.1016/S0145-2126(02)00077-2  0.56
2002 Frankel AE, Powell BL, Lilly MB. Diphtheria toxin conjugate therapy of cancer. Cancer Chemotherapy and Biological Response Modifiers. 20: 301-13. PMID 12703211  0.56
2002 Frankel AE, Powell BL, Hall PD, Case LD, Kreitman RJ. Phase I trial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemia Clinical Cancer Research. 8: 1004-1013. PMID 12006512  0.56
2002 Thomas PB, Delatte SJ, Sutphin A, Frankel AE, Tagge EP. Effective targeted cytotoxicity of neuroblastoma cells. Journal of Pediatric Surgery. 37: 539-44. PMID 11877684 DOI: 10.1053/jpsu.2002.30856  0.56
Show low-probability matches.